Stability of a flavored formulation of acetylcysteine for oral administration

American Journal of Health-System Pharmacy

Volumn 65, Issue 6, 2008, Pages 558-561

  Siden, Rivka ^a,b   Johnson, Cary E ^c,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^c Department of Pharmacy Practice

^d UMHHC ^*

Author keywords

Acetylcysteine; Chromatography, liquid; Concentration; Flavors; Mucolytic agents; Solutions; Stability; Storage; Temperature

Indexed keywords

ACETYLCYSTEINE; SWEETENING AGENT; ANTIDOTE; EXPECTORANT AGENT; PARACETAMOL;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; FREEZING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRESCRIPTION; PRIORITY JOURNAL; ROOM TEMPERATURE; STORAGE TEMPERATURE; HUMAN; INTOXICATION; ORAL DRUG ADMINISTRATION; SOLUTION AND SOLUBILITY; STANDARD; TEMPERATURE; TIME;

ACETAMINOPHEN; ACETYLCYSTEINE; ADMINISTRATION, ORAL; ANTIDOTES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; DRUG STORAGE; EXPECTORANTS; HUMANS; OVERDOSE; PHARMACEUTICAL SOLUTIONS; REFRIGERATION; SWEETENING AGENTS; TEMPERATURE; TIME FACTORS;

EID: 41049091892     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070433     Document Type: Article

References (21)

1. Acetylcysteine solution USP package insert. North Chicago, IL: Abbott Laboratories; 1998 Sep.
2. Acetadote injection package insert. Nashville, TN: Cumberland Pharmaceuticals Inc.; 2004 Mar.
3. Rowden AK, Norvell J, Eldridge DL et al. Updates on acetaminophen toxicity. Med Clin North Am. 2005; 89:1145-59.
4. Ziment I. Acetylcysteine: a drug that is much more than a mucokinetic. Biomed Pharmacother. 1988;42:513-9.
5. Kanter MZ. Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning. Am J Health-Syst Pharm. 2006;63:1821-7.
6. Grandjean EM, Berthet P, Ruffmann R et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther. 2000; 22:209-21.
7. Stey C, Steurer J, Bachmann S et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000; 16:253-62.
8. Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006;3:195-202.
9. Shalansky SJ, Pate GE, Levin A et al. N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration. Heart. 2005; 91:997-9.
10. Tepel M, Zidek W. N-acetylcysteine in nephrology; contrast nephropathy and beyond. Curr Opin Nephrol Hypertens. 2004; 13:649-54.
11. Hoffmann U, Fischereder M, Krüger B et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004; 15:407-10.
12. Miner SE, Dzavik V, Nguyen-Ho P et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004; 148:690-5.
13. Marenzi G, Assanelli E, Marana I et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006; 354:2773-82.
14. Thompson CA. Acetylcysteine's off-label use presents dosage-form issue. Am J Health-Syst Pharm. 2007; 64:1362,1364, 1368. News.
15. Zafarullah M, Li WQ, Sylvester J et al. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003; 60:6-20.
16. Altio M-L. N-acetylcysteine - passepartout or much ado about nothing? Br J Clin Pharmacol. 2005;61:5-15.
17. Eisbruch A, Ship JA, Martel MK et al. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. Int J Radiat Oncol Biol Phys. 1996;36:469-80.
18. Harrison LB, Zelefski MJ, Pfizer DG et al. Detailed quality of life assessment in patients with primary radiotherapy for squamous cell cancer of the base of tongue. Head Neck. 1997; 19:169-75.
19. Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys. 1994;28:847-56.
20. Anaizi NH, Swenson CF, Dentinger PJ. Stability of acetylcysteine in an extemporaneously compounded ophthalmic solution. Am J Health-Syst Pharm. 1997; 54:549-53.
21. Kiser TH, Oldland AR, Fish DN. Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings. Am J Health-Syst Pharm. 2007; 64:762-6.